维度生物 launches world's first 3D-printed PEEK patient-specific chest rib prosthesis, set for market

维度（西安）生物医疗科技有限公司, operating as Dimension Bio, has announced the imminent market launch of the world's first 3D-printed polyetheretherketone (PEEK) patient-specific chest rib prosthesis. Developed at the company's Xi'an High-tech Zone facility in Shaanxi Province, the implant leverages patient CT data for custom design and uses a controlled morphology and properties additive manufacturing process to create a biomimetic gradient modulus structure.总经理伍苏华 (General Manager Wu Suhua) stated the product is designed to address long-standing complications in chest wall reconstruction, including implant fracture, displacement, and X-ray artifact interference, with the regulatory and commercialization process now accelerating.

This development targets a persistent gap in thoracic surgery: chest rib defect reconstruction, where traditional solutions like autografts, titanium plates, or soft mesh patches each carry inherent limitations in mechanical matching, patient fit, and post-operative complication rates. Dimension Bio's PEEK implant, with its radiolucent properties and thermal conductivity closer to natural bone, directly challenges the titanium-alloy standard that has dominated this surgical space. The product's significance extends beyond its clinical utility; it represents a tangible output from Xi'an's maturing "产-学-研-医" (industry-academia-research-medical) collaborative ecosystem, supported by the Qinchuangyuan innovation platform and organizations like the Xi'an Lianchuang Biomedical Incubator. This ecosystem has cultivated over 500 biomedical enterprises and is now producing globally original medical device outcomes, shifting the narrative from isolated case breakthroughs to regional cluster competitiveness.

From a practical clinical and commercial standpoint, Dimension Bio's prosthesis addresses a genuine unmet need with a clear value proposition: reduced reoperation rates due to fewer mechanical failures, better post-operative respiratory function, and unimpeded post-surgical imaging surveillance. What remains to be seen is the implant's long-term in-vivo performance data at scale, the speed of hospital adoption and surgeon training, and the pricing relative to established titanium-based alternatives. For the additive manufacturing medical device landscape, this is a focused, application-specific win in a material class-PEEK-that has long promised patient-specific implants but has been slower to reach regulated commercial production.